2018
Assessment of a multimodal analgesia protocol to allow the implementation of enhanced recovery after cardiac surgery: Retrospective analysis of patient outcomes
Markham T, Wegner R, Hernandez N, Lee J, Choi W, Eltzschig H, Zaki J. Assessment of a multimodal analgesia protocol to allow the implementation of enhanced recovery after cardiac surgery: Retrospective analysis of patient outcomes. Journal Of Clinical Anesthesia 2018, 54: 76-80. PMID: 30412813, DOI: 10.1016/j.jclinane.2018.10.035.Peer-Reviewed Original ResearchMeSH KeywordsAgedAirway ExtubationAnalgesiaCardiopulmonary BypassClinical ProtocolsCoronary Artery BypassFemaleHealth Plan ImplementationHumansLength of StayMaleMiddle AgedOperating RoomsPain ManagementPain, PostoperativePatient Outcome AssessmentPerioperative CarePostoperative CareRetrospective StudiesTime FactorsConceptsMultimodal analgesia protocolCardiac surgeryHospital LOSAnalgesia protocolRetrospective analysisEnhanced recoveryPump coronary artery bypass graftControl groupIntensive care unit lengthPost-operative opioid consumptionCoronary artery bypass graftCardiac bypass timeOperating room extubationPost-op complicationsElective cardiac surgeryAortic clamp timeArtery bypass graftSingle-center studyType of surgeryTotal intubation timeCardio-pulmonary bypassICU LOSOpioid consumptionBypass timePerioperative outcomes
2016
Prognostic value and their clinical implication of 89-gene signature in glioma
Shahid M, Cho K, Nguyen M, Choi T, Jo Y, Aryal S, Yoo J, Yun H, Lee J, Eun Y, Lee J, Kang I, Ha J, Yoon H, Kim S, Kim S. Prognostic value and their clinical implication of 89-gene signature in glioma. Oncotarget 2016, 7: 51237-51250. PMID: 27323413, PMCID: PMC5239472, DOI: 10.18632/oncotarget.9983.Peer-Reviewed Original ResearchConceptsPrognostic valueHistological classificationGene signatureIndependent prognostic factorAggressive primary tumorAccurate prognostic valueWorst prognostic groupIndividual therapeutic outcomesAdjuvant chemotherapyOverall survivalPrognostic factorsPrognostic groupsPrimary tumorSubset analysisTumor groupIndividual patientsGlioma prognosisPatientsTherapeutic outcomesClinical implicationsClinical useIDH1 mutationPrognosisMicroarray chipGliomas